Pharmaceuticals - Active Pharmaceutical Ingredients (APIs) and Contract Development Manufacturing Organization (CDMO)
Strategic Profile
The company generates maximum revenue from Europe, followed by North America, Asia-Pacific, and the Rest of the world. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients, positioning it as a specialized player in high-complexity pharmaceutical ingredient manufacturing with growing biotechnology integration.
Cyborg Score Rationale
Euroapi holds a defensible market position as a specialized API and CDMO provider with strategic geographic footprint across Europe and North America. However, recent earnings show declining sales and mounting profitability pressures, reflecting industry headwinds and competitive intensity. The company's execution in navigating these challenges will determine recovery trajectory.
Top Insights
European API market leader with diversified product portfolio including vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, and opiates
Stock trading at €1.25 as of March 28, 2026, down significantly from 52-week high of €3.57, indicating investor concerns about business fundamentals